Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THINK: NKR-2 in refractory cancers
NCT03018405Phase 2Unknown
- Sponsor
- Celyad Oncology
- Start
- Dec 2016
- Primary completion
- May 2021
- Modality
- CAR-T Cells
- Countries
- 2
01
Overview
A Phase 2 trial of CAR-NKG2D in colorectal cancer (CRC), ovarian cancer, urothelial carcinoma (UC), triple-negative breast cancer (TNBC), pancreatic cancer (PC), sponsored by Celyad Oncology. Status: unknown.
02
Drugs
CAR-NKG2D
03
Conditions
colorectal cancer (CRC)ovarian cancerurothelial carcinoma (UC)triple-negative breast cancer (TNBC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03018405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03018405.